Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Tatsuya Ioka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0197-1832; OpenAlex author ID A5026988448. Sources: ClinicalTrials.gov.

Their work

Papers
59 (first author 9, last author 2)
Trials
1
Grants
0
Labs led
0
Collaborators
186
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: 5 papers, 1 trial · 2014: 3 papers · 2015: 4 papers · 2016: 5 papers · 2017: 5 papers · 2018: 5 papers · 2019: 3 papers · 2020: 3 papers · 2021: 5 papers · 2022: 1 paper · 2023: 7 papers · 2024: 3 papers · 2025: 2 papers · 2026: 3 papers

Papers 50 of 59

  1. Reconsidering upfront surgery for resectable pancreatic ductal adenocarcinoma: The role of risk stratification and neoadjuvant chemotherapy. Co-author DOI 10.1016/j.suronc.2025.102333↗
  2. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  3. Immature Peritumoral Tertiary Lymphoid Structures Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After NAC. Co-author DOI 10.21873/anticanres.18061↗
  4. Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospective Multi-Center Analysis (YPB-003). First author DOI 10.1002/cam4.70647↗
  5. The C11orf24 Gene as a Useful Biomarker for Predicting Severe Neutropenia in Modified FOLFIRINOX for Pancreatic Cancer. Co-author DOI 10.1111/cas.70087↗
  6. Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). First author DOI 10.1097/mpa.0000000000002323↗
  7. Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer. First author DOI 10.3390/cancers16142522↗
  8. [A Case of Pancreatic Cancer with Concomitant Pancreatic Metastasis of Renal Cell Carcinoma]. Co-author PMID 39948974↗
  9. Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort. Co-author DOI 10.1007/s00535-023-02033-3↗
  10. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  11. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
  12. Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety… Last author DOI 10.1093/jjco/hyac177↗
  13. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… First author DOI 10.1093/jjco/hyad044↗
  14. [Treatment strategy for unresectable locally advanced pancreatic adenocarcinoma]. Co-author DOI 10.11405/nisshoshi.120.643↗
  15. Efficacy of Staging Laparoscopy in Patients With Pancreatic Cancer: A Single Center Prospective Cohort Study. Co-author DOI 10.21873/invivo.13380↗
  16. New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancr… First author DOI 10.3389/fmed.2022.928182↗
  17. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  18. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  19. Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance. Co-author DOI 10.1097/mpa.0000000000001772↗
  20. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Co-author DOI 10.1097/mpa.0000000000001879↗
  21. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. Co-author DOI 10.3390/cancers13030502↗
  22. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Last author DOI 10.1002/cam4.3558↗
  23. Effectiveness of Contrast-Enhanced Ultrasonography for the Characterization of Small and Early Stage Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.ultrasmedbio.2020.04.016↗
  24. Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer. Co-author DOI 10.4251/wjgo.v12.i7.768↗
  25. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  26. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  27. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Panc… Co-author DOI 10.2169/internalmedicine.2362-18↗
  28. A case of stage IA pancreatic ductal adenocarcinoma accompanied with focal pancreatitis demonstrated by contrast-enhanced ultrasonography. Co-author DOI 10.1007/s10396-018-0870-5↗
  29. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic … Co-author DOI 10.1016/j.pan.2018.07.007↗
  30. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Co-author DOI 10.1097/mpa.0000000000001052↗
  31. Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001140↗
  32. The Role of Transabdominal Ultrasound in the Diagnosis of Early Stage Pancreatic Cancer: Review and Single-Center Experience. Co-author DOI 10.3390/diagnostics9010002↗
  33. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gem… Co-author DOI 10.1007/s00280-017-3351-4↗
  34. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  35. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Co-author DOI 10.1016/j.cca.2017.02.011↗
  36. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2016.436↗
  37. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  38. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-016-2972-3↗
  39. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Co-author DOI 10.1007/s00280-016-3121-8↗
  40. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  41. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-B… Co-author DOI 10.1371/journal.pone.0161009↗
  42. Prospective small bowel mucosal assessment immediately after chemoradiotherapy of unresectable locally advanced pancreatic cancer using capsule endoscopy: a ca… Co-author DOI 10.20524/aog.2016.0063↗
  43. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Co-author DOI 10.1038/srep15921↗
  44. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global ra… Co-author DOI 10.1093/jjco/hyv011↗
  45. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Co-author DOI 10.1111/cas.12709↗
  46. [The progress of chemotherapy for advanced pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.2119↗
  47. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Co-author DOI 10.1002/jhbp.130↗
  48. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1111/cas.12501↗
  49. Duodenal Hemorrhage from Pancreatic Cancer Infiltration Controlled through Combination Therapy with Gemcitabine and S-1. First author DOI 10.1159/000364819↗
  50. Risk of peritoneal carcinomatosis by endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Co-author DOI 10.1007/s00535-012-0693-x↗

Trials 1

  1. A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer Study director NCT02272738↗

Closest collaborators

The 25 strongest of 186 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takuji Okusaka · 29 shared papers, 2011–2026 · strength 2.10
  2. Yoshitaro Shindo · 9 shared papers, 2021–2026 · strength 1.79
  3. Hiroto Matsui · 9 shared papers, 2021–2026 · strength 1.79
  4. Junji Furuse · 24 shared papers, 2011–2026 · strength 1.78
  5. Masafumi Ikeda · 18 shared papers, 2013–2026 · strength 1.62
  6. Hiroaki Nagano · 8 shared papers, 2021–2026 · strength 1.60
  7. Hidenori Takahashi · 11 shared papers, 2013–2026 · strength 1.54
  8. Makoto Ueno · 14 shared papers, 2016–2026 · strength 1.48
  9. Masao Nakajima · 7 shared papers, 2023–2026 · strength 1.44
  10. Ryouichi Tsunedomi · 5 shared papers, 2021–2026 · strength 1.05
  11. Nobumasa Mizuno · 11 shared papers, 2016–2023 · strength 0.87
  12. Kazuyoshi Ohkawa · 7 shared papers, 2013–2026 · strength 0.80
  13. Shoji Nakamori · 13 shared papers, 2011–2021 · strength 0.74
  14. Reiko Ashida · 8 shared papers, 2013–2022 · strength 0.71
  15. Hiroshi Ishii · 9 shared papers, 2013–2023 · strength 0.67
  16. Hiroaki Nagano · 3 shared papers, 2019–2024 · strength 0.65
  17. Yusaku Watanabe · 3 shared papers, 2024–2026 · strength 0.64
  18. Masato Ozaka · 6 shared papers, 2014–2026 · strength 0.61
  19. Ryoji Takada · 6 shared papers, 2014–2023 · strength 0.60
  20. Hideki Ueno · 9 shared papers, 2013–2021 · strength 0.57
  21. Akira Fukutomi · 8 shared papers, 2013–2021 · strength 0.54
  22. Shinichi Ohkawa · 11 shared papers, 2011–2019 · strength 0.52
  23. Kenji Ikezawa · 5 shared papers, 2013–2022 · strength 0.49
  24. Kazuhiro Katayama · 5 shared papers, 2018–2021 · strength 0.48
  25. Sachiko Tanaka · 7 shared papers, 2012–2021 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.